| abstract |
Disclosed are 2-amino-5-(alkoxy/phenoxyl)-4-(5-amino)pyrimidine derivatives and analogues as represented by the general formula (I), or a pharmaceutically acceptable salt, tautomer, solvate or polymorph thereof, wherein R1 is hydrogen, alkyl, cyclopropyl, alkoxy, halogen, hydroxyl or trifluoromethyl; R2 is alkyl, alkoxyalkyl, cycloalkyl, heterocycle, aryl, bicyclic heterocycle, alkylaryl, heteroaryl and alkylheteroaryl, each of which is optionally substituted; R3 is alkyl, alkoxy, alkenyl or alkynyl, each of which is optionally substituted; and wherein the remaining substituents are as defined herein. Representative compounds include 2-amino-5-((3,4-dimethoxypyridin-2-yl)methoxy)-4-(hydroxyhexan-3-yl)amino)pyrimidine, 2-amino-5-methoxy-4-(hydroxyheptan-3-yl)amino)pyrimidine, and 2-amino-5-((3,4-dimethoxypyridin-2-yl)methoxy)-4-(butylamino)pyrimidine. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) as defined above or a pharmaceutically acceptable salt, tautomer, solvate or polymorph thereof together with one or more pharmaceutically acceptable excipients, diluents or carriers, for use in the treatment of a disorder or disease in which the modulation of TLR7 and /or TLR8 is involved, and for the treatment of viral infections, such as hepatitis C virus. |